Publications by authors named "Andrzej J Jakubowiak"

49Publications

Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic.

Clin Lymphoma Myeloma Leuk 2020 Sep 4;20(9):e543-e546. Epub 2020 May 4.

Department of Pharmacy, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.012DOI Listing
September 2020

Clinician attitudes and practices toward measurable residual disease in multiple myeloma.

Br J Haematol 2020 Aug 7;190(3):470-472. Epub 2020 Jun 7.

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16805DOI Listing
August 2020

Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.

Cancer Med 2020 01 12;9(1):324-334. Epub 2019 Nov 12.

Department of Medicine, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943155PMC
January 2020

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.

Hematology 2017 Dec 25;22(10):585-591. Epub 2017 May 25.

c Department of Clinical Development , Amgen Inc., One Amgen Center Drive , Thousand Oaks , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245332.2017.1328165DOI Listing
December 2017

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Leuk Lymphoma 2015 12;56(10):2959-61. Epub 2015 May 12.

g John Theurer Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1020801DOI Listing
September 2016

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

Cancer Treat Rev 2014 Jul 1;40(6):781-90. Epub 2014 Mar 1.

Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637-6613, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.02.005DOI Listing
July 2014

Current approaches to the initial treatment of symptomatic multiple myeloma.

Int J Hematol Oncol 2013 Feb;2(1)

Section of Hematology/Oncology, Department of Medicine & Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh.13.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839860PMC
February 2013

Evolving strategies in the initial treatment of multiple myeloma.

Semin Oncol 2013 Oct;40(5):592-601

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL; Comprehensive Cancer Center, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.08.002DOI Listing
October 2013

Introduction: recent advances in the understanding and management of multiple myeloma.

Semin Oncol 2013 Oct;40(5):535-6

The University of ChicagoChicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.08.003DOI Listing
October 2013

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Clin Adv Hematol Oncol 2011 Apr;9(4):1-15

Chief Myeloma Division, John Theuer Cancer Center, Hackensack, New Jersey, USA.

View Article

Download full-text PDF

Source
April 2011

Monoclonal antibodies in the treatment of multiple myeloma.

Br J Haematol 2011 Sep 21;154(6):745-54. Epub 2011 Jul 21.

Dana-Farber Cancer Institute, Boston, MA, USADepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USACentre Rene Gauducheau, Nantes, France.

View Article

Download full-text PDF

Source
http://deepblue.lib.umich.edu/bitstream/handle/2027.42/86883
Web Search
http://doi.wiley.com/10.1111/j.1365-2141.2011.08790.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2011.08790.xDOI Listing
September 2011

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.

Leuk Lymphoma 2010 Jul;51(7):1178-87

Department of Neurosciences and Biomedical Technologies, University of Milan-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.483303DOI Listing
July 2010

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

J Clin Oncol 2009 Oct 8;27(30):5015-22. Epub 2009 Sep 8.

Comprehensive Cancer Center, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109-5936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.5370DOI Listing
October 2009

Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.

Proc Natl Acad Sci U S A 2007 Dec 27;104(49):19488-93. Epub 2007 Nov 27.

Department of Dermatology, Comprehensive Cancer Center, and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0708380104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2148316PMC
December 2007